Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

AI automates testing of implant coatings

The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect coated implants.

How the Foreign Office will promote Swedish life science exports

The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...

Conference recordings now available

Don't miss out on insights from leading experts.

The business coach: “We need to learn from our mistakes”

The past year has been challenging for many biotech companies, with several comapanies facing financial stress and bankruptcy. To understand how entrepreneurs c...

Mercodia AB

ZEISS Quality Innovations at CONTROL

May 6-9, 2025 in Stuttgart.

Security flaw in Swedish breast cancer screening software – woman passed away

A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...

Studie: Eli Lillys Mounjaro överglänser Novo Nordisks Wegovy

På fem olika mål för viktminskning, inklusive minskning av midjeomfång, är Eli Lillys Mounjaro överlägsen Novo Nordisks Wegovy, enligt resultatet från en första...

Life science trends 2025 – The economy

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...

Björn Arvidsson: ”We must raise our gaze to find the answers of the future”

A system approach isn't just about understanding complexity – it's about making better decisions. By seeing ourselves as part of larger systems, we can better a...

Cost-efficient development of laboratory devices

8 ways to optimise development costs and speed up processes

ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin

More than 50 distinguished speakers from leading manufacturing companies.

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

Product demo with features, software and best-practices

Get interesting insights about ZEISS O-INSPECT duo in our demo recording.

AI-Driven Microscopy Image Analysis in Pharma and Biotech

Extract breakthrough discoveries from large, complex data sets.

He takes over the chairmanship of Karolinska Development

Ben Toogood is appointed as the new chairman of Karolinska Developments.

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

Scale Up Your Image Analysis

ZEISS arivis Hub for accelerated analysis and faster results.

The US is leaving the WHO

The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.